目的 研究比索洛爾治療原發(fā)性高血壓的有效性及安全性。方法 應用Meta分析對11篇文獻研究中比索洛爾與其他常用抗高血壓藥治療原發(fā)性高血壓的有效性、安全性進行同質性檢驗及合并效應量的估計。結果 同質性檢驗的有效性：χ²＝9.347 3，df＝10；安全性：χ²＝4.054 9，df＝10；P＞0.05。合并效應量的估計：有效性：OR_合并95%可信區(qū)間為1.53～3.06。安全性：OR_合并的檢驗：χ²＝19.592 9，P＜0.001。結論 比索洛爾治療原發(fā)性高血壓的療效總體上優(yōu)于目前其他藥物，而且安全性比較無顯著性差異。

Objective To evaluate the safety and efficiency of bisoprolol in treatment of essential hypertension. Methods The homogeneity test and merging effect value estimation on the efficacy and safety of Bisoprolol and other antihypertensive drugs in the treatment of essential hypertension were carried out using Meta-analysis, which was reported in 11 research papers. Results Homogeneity test showed that the cited studies of efficacy and safety were homogenous: χ² = 9.347 3 (df = 10) and χ² = 4.054 9 (df = 10) (P > 0.05). The results of merging effect value estimation were as follows: 95% confidence interval of OR_merging was 1.53—3.06. The result of OR_merging test was χ² = 19.592 9, P > 0.001. Conclusion The effect of Bisoprolol on essential hypertension is better than that of other drugs, in addition, the safty has no significant difference between Bisoprolol and other drugs.